Skip to main content

Advertisement

SpringerLink
Log in

Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are new targets in cancer immunotherapy in recent years. The aim of this study is to evaluate the PD-1/PD-L1 expressions in sarcomas and to determine association between PD-1/PD-L1 expressions and clinical/pathological properties in some sarcoma subtypes. Formalin-fixed, paraffin-embedded tissue samples from 65 cases with sarcomas were analyzed. Immunohistochemical staining was performed to detect the PD-1 and PD-L1 expressions in tumor tissue and microenvironment, separately. PD-1 expression in tumor tissue and microenvironment was detected in 11 (17 %) and 8 (12 %) cases, respectively. PD-L1 expression in tumor tissue and microenvironment was detected in 19 (29 %) and 20 cases (30 %), respectively. None of the 5 Ewing sarcomas involving bone showed PD-1/PD-L1 expression, while 2 of 3 cases with Ewing sarcomas involving soft tissue showed PD-1 and PD-L1 expression. Among 5 cases with Kaposi sarcoma, four showed PD-1 and/or PD-L1 expression in tumor or microenvironment. PD-1/PD-L1 expressions were detected 3 of 6 cases with pleomorphic sarcoma, 2 of 4 cases with peripheral nerve sheath tumors and 1 of 4 cases with synovial sarcoma. Interestingly, strongest PD-1/PD-L1 expressions in our study group were detected in 2 sarcoma cases with the history of giant cell tumor. PD-1 and PD-L1 expressions are up to 30 % of the cases with sarcomas. It may be rational to target programmed death pathway in Kaposi sarcoma, pleomorphic sarcoma and peripheral nerve sheath tumors. Strong expression of PD-1/PD-L1 in cases with previous giant cell bone tumor has been found to be interesting and must be studied in giant cell tumor samples.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111:2214–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290:84–9.

    Article  CAS  PubMed  Google Scholar 

  3. Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget. 2016. doi:10.18632/oncotarget.9316.

    Google Scholar 

  4. Dong L, Lv H, Li W, Song Z, Li L, Zhou S, Qui L, Qian Z, Liu X, Feng L, Meng B, Fu K, Wang X, Pan-Hammarström Q, Wang P, Wang X, Zhang H. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/m TOR pathway in tumor cells. Oncotarget. 2016. doi:10.18632/oncotarget.9061.

    Google Scholar 

  5. Chen K, Chen G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W, Su D. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2016. doi:10.18632/oncotarget.8956.

    Google Scholar 

  6. Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016;141:293–302.

    Article  CAS  PubMed  Google Scholar 

  7. Paydas S, Bağır E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol. 2015;94:1545–52.

    Article  CAS  PubMed  Google Scholar 

  8. Burgess M, Gorantla V, Weis K, Tawbi H. Immunotherapy in sarcoma: future horizons. Curr Oncol Rep. 2015;17:52.

    Article  PubMed  Google Scholar 

  9. Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14:199–220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zheng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget. 2016;7(8):8944–55. doi:10.18632/oncotarget.6884.

    Google Scholar 

  11. Koh YW, Jeon YK, Yoon DH, Suh C, Huh J. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumour Biol. 2016;37:7507–14.

    Article  CAS  PubMed  Google Scholar 

  12. Zhang L, Qiu M, Jin J, Li B, Wang X, Yan S, Xu R, Yang D. Programmed cell death ligand 1 (P-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol. 2015;8:11084–91.

    PubMed  PubMed Central  Google Scholar 

  13. Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1 and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015;6(28):26483–93. doi:10.18632/oncotarget.4494.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One. 2015;10(8):e0136023.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One. 2015;10(6):e0131403. doi:10.1371/journal.pone.0131403.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Tine BAV. Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget. 2015;6:12234–47.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, Kang MJ, Jang KY. Tumor infiltrating PD-1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8(12):e82870. doi:10.1371/journal.pone.0082870.

    Article  PubMed  PubMed Central  Google Scholar 

  18. D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357–65.

    Article  PubMed  Google Scholar 

  19. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2:690–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zheng W, Xiao H, Liu H, Zhou Y. Expression of programmed death 1 is correlated with progression of osteosarcoma. APMIS. 2014;123:102–7.

    Article  PubMed  Google Scholar 

  21. Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10:707–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with antiretroviral therapy: prospective cohort study. BMJ. 1999;31:23–4.

    Article  Google Scholar 

  23. Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison od sarcomatous and carcinomatous areas. Eur J Cancer. 2015;51:2698–707.

    Article  CAS  PubMed  Google Scholar 

  24. Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas Show high levels of programmed deat ligand-1 (PD-L1). J Thorac Oncol. 2013;8:803–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study has been supported by Cukurova University Research Fund.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey

    Semra Paydas

  2. Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey

    Emine Kilic Bagir & Gulfiliz Gonlusen

  3. Department of Orthopedics, Faculty of Medicine, Cukurova University, Adana, Turkey

    Mehmet Ali Deveci

Authors
  1. Semra Paydas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emine Kilic Bagir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehmet Ali Deveci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gulfiliz Gonlusen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Semra Paydas.

Ethics declarations

Conflict of interest

None.

Additional information

This study has been submitted to ESMO 2016 meeting.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paydas, S., Bagir, E.K., Deveci, M.A. et al. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol 33, 93 (2016). https://doi.org/10.1007/s12032-016-0807-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-016-0807-z

Keywords

Search

Navigation